These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36002595)

  • 21. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
    Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
    Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection.
    Deng H; Fan X; Wang X; Zeng L; Zhang K; Zhang X; Li N; Han Q; Lv Y; Liu Z
    Sci Rep; 2020 Nov; 10(1):20276. PubMed ID: 33219288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenosine Triphosphate in Serum as a Promising Biomarker for Differential Diagnosis of Hepatitis B Disease Progression.
    Lin C; Huang Y; Luo L; Fang F; Zhang J; Xun Z; Fu Y; Shang H; Liu C; Ou Q
    Front Immunol; 2022; 13():927761. PubMed ID: 35844530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exportin 4 gene expression and DNA promoter methylation status in chronic hepatitis B virus infection.
    Zhang F; Fan YC; Mu NN; Zhao J; Sun FK; Zhao ZH; Gao S; Wang K
    J Viral Hepat; 2014 Apr; 21(4):241-50. PubMed ID: 24597692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases.
    Wu L; Pan Q; Wu G; Qian L; Zhang J; Zhang L; Fang Q; Zang G; Wang Y; Lau G; Li H; Jia W
    Sci Rep; 2017 Nov; 7(1):16482. PubMed ID: 29184085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
    Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study.
    Wang R; Zang W; Hu B; Deng D; Ling X; Zhou H; Su M; Jiang J
    Technol Cancer Res Treat; 2020; 19():1533033820980785. PubMed ID: 33308056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA Profiling Analysis of the Serum Exosomes Derived from Patients with Chronic Hepatitis and Acute-on-chronic Liver Failure Caused By HBV.
    Chen J; Xu Q; Zhang Y; Zhang H
    Sci Rep; 2020 Jan; 10(1):1528. PubMed ID: 32001731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
    Han LY; Yang JR; Zhao ZH; Gao S; Fan YC; Wang K
    Pathol Res Pract; 2020 Oct; 216(10):153147. PubMed ID: 32853963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of candidate biomarkers from plasma-derived extracellular vesicles of patients with cirrhosis and hepatocellular carcinoma: an exploratory proteomic study.
    Zertuche-Martínez C; Velázquez-Enríquez JM; González-García K; Santos-Álvarez JC; Romero-Tlalolini MLÁ; Pina-Canseco S; Pérez-Campos Mayoral L; Muriel P; Villa-Treviño S; Baltiérrez-Hoyos R; Arellanes-Robledo J; Vásquez-Garzón VR
    Mol Omics; 2024 Aug; 20(7):483-495. PubMed ID: 39011654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of PNPLA3, TM6SF2 gene polymorphisms and its interactions with smoking and alcohol drinking on hepatitis B virus-associated hepatocellular carcinoma].
    Wang LQ; Guo WH; Guo ZW; Qin P; Zhang R; Zhu XM; Liu DW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1611-1616. PubMed ID: 30572387
    [No Abstract]   [Full Text] [Related]  

  • 33. The trajectory of vesicular proteomic signatures from HBV-HCC by chitosan-magnetic bead-based separation and DIA-proteomic analysis.
    Cao L; Zhou Y; Lin S; Yang C; Guan Z; Li X; Yang S; Gao T; Zhao J; Fan N; Song Y; Li D; Li X; Li Z; Guan F; Tan Z
    J Extracell Vesicles; 2024 Sep; 13(9):e12499. PubMed ID: 39207047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression.
    Huyen PTM; Dung DTN; Weiß PJ; Hoan PQ; Giang DP; Uyen NT; Van Tuan N; Trung NT; Velavan TP; Song LH; Hoan NX
    Int J Infect Dis; 2022 Feb; 115():229-236. PubMed ID: 34910956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
    Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
    Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma.
    Yang C; Chen H; Zhou B; Yin J; Cao G; Hou J; Jiang D
    Mol Carcinog; 2022 Oct; 61(10):933-940. PubMed ID: 35880842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-Depth Serum Proteomics Reveals the Trajectory of Hallmarks of Cancer in Hepatitis B Virus-Related Liver Diseases.
    Xu M; Xu K; Yin S; Chang C; Sun W; Wang G; Zhang K; Mu J; Wu M; Xing B; Zhang X; Han J; Zhao X; Wang Y; Xu D; Yu X
    Mol Cell Proteomics; 2023 Jul; 22(7):100574. PubMed ID: 37209815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma.
    Tat Trung N; Duong DC; Tong HV; Hien TTT; Hoan PQ; Bang MH; Binh MT; Ky TD; Tung NL; Thinh NT; Sang VV; Thao LTP; Bock CT; Velavan TP; Meyer CG; Song LH; Toan NL
    PLoS One; 2018; 13(4):e0196081. PubMed ID: 29672637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
    J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Hu HH; Liu J; Lin YL; Luo WS; Chu YJ; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; You SL; Yang HI; Chen CJ;
    Gut; 2016 Sep; 65(9):1514-21. PubMed ID: 26642861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.